Gilder Gagnon Howe & Co. LLC Has $203.69 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Gilder Gagnon Howe & Co. LLC lowered its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 7.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,286,728 shares of the medical research company's stock after selling 103,743 shares during the quarter. Natera comprises approximately 2.2% of Gilder Gagnon Howe & Co. LLC's holdings, making the stock its 10th largest holding. Gilder Gagnon Howe & Co. LLC owned 0.97% of Natera worth $203,689,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of NTRA. Blue Trust Inc. boosted its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. increased its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its stake in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after acquiring an additional 332 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 2,562 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares in the company, valued at $10,457,844.37. This represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gail Boxer Marcus sold 4,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total transaction of $590,760.00. Following the transaction, the director now directly owns 9,704 shares of the company's stock, valued at $1,433,183.76. The trade was a 29.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 197,301 shares of company stock worth $30,325,031 over the last three months. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. BTIG Research reissued a "buy" rating on shares of Natera in a research note on Friday, February 28th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. Barclays decreased their target price on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Natera Price Performance

Natera stock traded up $1.90 during midday trading on Tuesday, reaching $154.89. The company had a trading volume of 931,651 shares, compared to its average volume of 1,379,531. The firm's fifty day simple moving average is $147.29 and its 200-day simple moving average is $153.88. The company has a market capitalization of $20.94 billion, a P/E ratio of -88.01 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 12-month low of $92.01 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.